Therapeutic areas
Where disease burden meets development need.
The indications we are equipped to run, grouped by clinical family. If yours is not listed, ask — protocol fit matters more than the label.
Showing 15 therapeutic areas
- Oncology & immunology
Oncology
Solid tumour and haematological malignancy studies, including RECIST-based response assessment and central imaging coordination.
- Oncology & immunology
Immunology
Autoimmune and inflammatory conditions, with biologic and small-molecule programmes across rheumatology and dermatology.
- Oncology & immunology
Haematology
Anaemias, haemoglobinopathies and coagulation disorders — areas with substantial regional patient populations.
- Chronic disease
Endocrinology & Metabolism
Type 1 and type 2 diabetes, obesity, thyroid and metabolic syndrome studies drawing on a high regional disease burden.
- Chronic disease
Cardiology
Hypertension, dyslipidaemia, heart failure and acute coronary syndrome trials with ECG and echo core-lab coordination.
- Chronic disease
Nephrology
Chronic kidney disease, diabetic nephropathy and dialysis-population studies.
- Chronic disease
Respiratory
Asthma, COPD and interstitial lung disease studies with spirometry standardisation.
- Chronic disease
Gastroenterology & Hepatology
Inflammatory bowel disease, chronic hepatitis B and C, and non-alcoholic fatty liver disease programmes.
- Infectious disease
Infectious Diseases
Anti-infective and antiviral studies, including hospital-acquired and community-acquired infection programmes.
- Infectious disease
Vaccines
Prophylactic vaccine studies with cold-chain management, large-cohort enrolment and community engagement models.
- Infectious disease
Tuberculosis
Drug-sensitive and drug-resistant TB regimens, an area where regional patient access is a genuine strategic advantage.
- Specialty
Neurology
Epilepsy, stroke, neuropathic pain and neurodegenerative disease studies with rater training and scale standardisation.
- Specialty
Psychiatry
Depression, anxiety and schizophrenia studies with certified rating-scale administration.
- Specialty
Dermatology
Psoriasis, atopic dermatitis and chronic urticaria trials with standardised photography.
- Specialty
Ophthalmology
Diabetic retinopathy, macular degeneration and glaucoma studies with imaging-reading-centre coordination.
The case for Pakistan
Where the patients are, trials follow.
High disease burden, a large and young population, and comparatively low trial saturation — the conditions under which enrolment targets are met rather than negotiated down.
241M
people
The world's fifth most populous country, with a young, largely treatment-naïve population.
Source: Pakistan Bureau of Statistics, 2023 Census(opens in a new tab)33M
adults living with diabetes
The third-largest diabetic population globally, and the highest national prevalence (26.7%).
Source: IDF Diabetes Atlas, 10th edition (2021)(opens in a new tab)#1
hepatitis C burden worldwide
An estimated 9 million people living with HCV — more than any other country.
Source: WHO Global Hepatitis Report 2024(opens in a new tab)6.3%
of global TB cases
One of the five countries that together account for more than half of the world's tuberculosis.
Source: WHO Global Tuberculosis Report 2024(opens in a new tab)
Your indication
Planning a study in an area not listed? Ask us.
Tell us the indication, phase and target enrolment. We will give you an honest view of feasibility in Pakistan before anything else.